Predictive Interpretability of Machine Learning Models for In-Hospital Bleeding Risk Following PCI in Diabetic Patients with Acute Coronary Syndrome: A Retrospective Analysis - Report - MDSpire

Predictive Interpretability of Machine Learning Models for In-Hospital Bleeding Risk Following PCI in Diabetic Patients with Acute Coronary Syndrome: A Retrospective Analysis

  • By

  • Huasheng Lv

  • Ruotong Cao

  • Yuchen Zhang

  • Fengyu Sun

  • Yitong Ma

  • Xinrong Zhou

  • February 20, 2026

  • 0 min

Share

Clinical Report: Predictive Interpretability of Machine Learning Models for In-Hospital Bleeding Risk Following PCI in Diabetic Patients

Overview

This study develops and validates machine learning models to predict in-hospital bleeding risk after PCI in diabetic patients with acute coronary syndrome. The models utilize SHAP for interpretability, enhancing clinical trust and risk stratification.

Background

Diabetes significantly increases the risk of cardiovascular diseases, particularly acute coronary syndrome (ACS), complicating treatment strategies like percutaneous coronary intervention (PCI). The risk of bleeding complications post-PCI poses a serious challenge, necessitating accurate risk prediction tools tailored for diabetic patients. Traditional bleeding risk scores may not adequately address the unique risk profiles of these patients, highlighting the need for advanced predictive models.

Data Highlights

No numerical data available in the provided text.

Key Findings

  • Machine learning models were developed to predict in-hospital bleeding in diabetic patients post-PCI.
  • SHAP was utilized to enhance the interpretability of the machine learning models.
  • Traditional bleeding risk scores may not be suitable for diabetic patients undergoing PCI.
  • Diabetic patients face a higher risk of both ischemic and bleeding complications.
  • Accurate risk prediction can aid in clinical decision-making and improve patient outcomes.

Clinical Implications

Healthcare professionals should consider the use of machine learning models to better assess bleeding risks in diabetic patients undergoing PCI. The interpretability of these models can facilitate informed clinical decisions and enhance patient safety.

Conclusion

The integration of machine learning and interpretability techniques represents a promising advancement in predicting bleeding risks for diabetic patients post-PCI, potentially improving clinical outcomes.

References

  1. Frontiers in Digital Health, 2026 -- Creation and validation of interpretable machine learning models for assessing the risk of pancreatic pseudocyst formation in acute pancreatitis patients
  2. AACE Endocrine AI, 2026 -- Synthetic data boosts readmission prediction
  3. Basic Research in Cardiology, 2023 -- A Cardiologist's Perspective on Utilizing Machine Learning for Predicting Outcomes in Cardiovascular Disease
  4. npj Digital Medicine, 2026 -- A deep learning model integrating structured data and clinical text for predicting atrial fibrillation recurrence
  5. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes | European Heart Journal | Oxford Academic
  6. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 - PubMed
  7. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium - PubMed
  8. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes | European Heart Journal | Oxford Academic
  9. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 - PubMed
  10. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium - PubMed

Original Source(s)

Related Content